ClinicalTrials.gov
public full text
Public Domain
Dupilumab De-escalation in Pediatric Atopic Dermatitis
This is a pilot investigator-blinded, randomized clinical trial to assess the feasibility of dupilumab treatment discontinuation or dose-reduction in children aged 1-17 years who have achieved sustained atopic dermatitis (AD) control on dupilumab.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Dupilumab en el tratamiento de pacientes pediátricos con dermatitis atópica moderada a severa en Chile. Serie de 10 casos clínicos#483700
- Severity bands for atopic dermatitis measures: analysis from adult dupilumab randomized clinical trials / Andreas Wollenberg, Eric L. Simpson, Yael A. Leshem, Alain Taïeb, Norito Katoh, Jingdong Chao, Ana B. Rossi, Amy H. Praestgaard#783932
- Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD)#982638
- Safety and Tolerability of Dupilumab in Participants With Moderate to Severe Atopic Dermatitis#866564
- Neuropsychologic Assessments of Dupilumab-Treated Adolescent Participants With Moderate-to-Severe Atopic Dermatitis#1008471
Record · ID 835866
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive